43 results on '"Fung, Henry C"'
Search Results
2. A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma
3. Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation
4. A Single Center Retrospective Analysis Comparing the Outcomes of Induction Therapy between 7+3 and FLAG-IDA/Venetoclax in Newly Diagnosed Patients with Acute Myeloid Leukemia
5. Molecular Monitoring with Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma
6. Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
7. Engineering of CD19-Specific Chimeric Antigen Receptor T Cells with the Integrin CD103 Results in Augmented Therapeutic Efficacy Against Human Lymphoma in a Preclinical Model
8. Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial
9. Engraftment Kinetics After Alimtuzumab-Based Allogeneic Stem Cell Transplant (SCT): Full Donor T-Cell Chimerism Did Not Predict for Acute Graft Versus Host Disease (GVHD) or CMV Reactivation
10. Chemo-Mobilization Provides Superior Mobilization and Collection in Autologous Stem Cell Transplants but with Less Predictability and At a Higher Cost,
11. Efficacy of Plerixafor Administered At 5:00PM for Stem Cell Mobilization in Lymphoma and Myeloma Patients Undergoing Autologous Stem Cell Transplant,
12. Differences in Stem Cell Collection Practices and Related Outcomes Between Centers That Conduct and Do Not Conduct Aphaeresis on Weekends
13. A Long-Term Follow-up Report on Autologous Hematopoetic Cell Transplant (AuHCT) for Patients with Hodgkin Lymphoma — Limited Utility of Post-Transplant Surveillance Computerized Axial Tomography (CAT scan) and/or PET Scan,
14. Update on a Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine, Mitoxantrone and Rituximab Followed by Yttrium-90 Ibritumomab Tiuxetan and Maintenance Rituximab as Front Line Therapy for Patients with Indolent Lymphomas
15. Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study
16. Cytokine Treatment of CD34+ Cord Blood Cells with G-CSF, GM-CSF, or SCF During 48 Hours of Ex Vivo Culture Alters CD26/DPPIV Peptidase Activity and Subsequent Engraftment Into NSG Immunodeficient Mice.
17. Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem Cell Transplantation (HSCT) Using a Conservative Medical Therapy Approach.
18. CD26 Inhibition Preferentially Enhances In Vitro Migration of G-CSF + Plerixafor (AMD3100) Mobilized PB as Compared to G-CSF Mobilized PB In Multiple Myeloma Autografts.
19. Efficacy of Administration of Plerixafor (Mozobil®) at 5:00 PM for Stem Cell Mobilization (SCM) in Patients Receiving Autologous Stem Cell Transplant.
20. The Transplant Outcomes of a 10/10 Matched Unrelated Donor (MUD) Stem Cell Transplant (SCT) Is Similar to a HLA Identical Related Donor (RD) Transplant.
21. CD26 Inhibitor Treated and CD26−/− Recipient Mice Exhibit Improved Transplant Efficiency as Quantitated by Increased Short-Term Homing and Long-Term Engraftment
22. The Role of FDG-PET in Hodgkin Lymphoma S/P Autologous Hematopoietic Cell Transplant (HCT) as a Predictor of Outcome.
23. Reversal of Renal Insufficiency after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
24. Cytogenetic Analysis and FISH in the Evaluation of Patients with MDS: A Retrospective Analysis of Concordance Rate, Utility and Benefit of Performing Both Studies Simultaneously
25. Disruption of CXCR4 Utilizing AMD3100 Bypasses Mobilization Deficiency Exhibited by CD26−/− Mice and Results in Efficient Mobilization of Myeloid Progenitors
26. Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb®2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
27. Abnormally High Levels of Circulating CD34+CD38−, CD34+CD38+, and CD10+ Hematopoietic Stem and Progenitor Cells in the Peripheral Blood of B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Suggest the Presence of Additional Therapeutic Target Cells.
28. Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Pateints (pts) with Advanced Chronic Lymphoctic Leukemia (CLL): A Comparative Study.
29. Incorporating Target Immunotherapy into Standard Conditioning Regimen Prior to Autologous Stem Cell Transplantaion (ASCT) Improves the Transplant Outcome for Pateints with Relapsed/Refractroy B Cell Non-Hodgkin Lymphoma (B-NHL).
30. Hematopoietic Cell Transplantation - Comorbidity Index (HCT-CI) as a Surrgoate Marker for Predition of Transplant Outcome for Pateints (pts) with Multiple Myeloma (MM) Undergoing Autologous Stem Cell Transplantation (ASCT): High HCT-CI Score Predicts for Poor Outcome.
31. A Prospective Study Evaluating the Safety and Efficacy of Combination Therapy with Fludarabine Plus Mitoxantrone Followed by Yttrium-90 (90Y) Ibritumomab Tiuxetan (Zevalin®) and Maintenance Rituximab as Front Line Therapy for Patients with Intermediate or High Risk Follicular Non-Hodgkin’s Lymphoma.
32. A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.
33. Predicting Steroid Refractroy Acute Gastrointestinal (GI) Acute Graft Versus Host Disease (AGVHD) by Assessment of Crypt Loss at Diagnosis.
34. 90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.
35. Final Report on Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Poor Risk Recurrent Hodgkin Lymphoma - A Two Institution Study.
36. Impact of Allogeneic Stem Cell Transplantation (ASCT) on Outcome of Biphenotypic Acute Leukemia (BAL):.
37. The Use of Reduced Intensity Allogeneic Stem Cell Transplantation (alloSCT) for Recurrence after Autologous Stem Cell Transplantation (ASCT) in Hodgkin’s Disease (HD).
38. Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation
39. CD26 Inhibition Preferentially Enhances In VitroMigration of G-CSF + Plerixafor (AMD3100) Mobilized PB as Compared to G-CSF Mobilized PB In Multiple Myeloma Autografts.
40. Cytokine Treatment of CD34+Cord Blood Cells with G-CSF, GM-CSF, or SCF During 48 Hours of Ex VivoCulture Alters CD26/DPPIV Peptidase Activity and Subsequent Engraftment Into NSG Immunodeficient Mice.
41. Disruption of CXCR4 Utilizing AMD3100 Bypasses Mobilization Deficiency Exhibited by CD26−/−Mice and Results in Efficient Mobilization of Myeloid Progenitors
42. CD26 Inhibitor Treated and CD26−/−Recipient Mice Exhibit Improved Transplant Efficiency as Quantitated by Increased Short-Term Homing and Long-Term Engraftment
43. Abnormally High Levels of Circulating CD34+CD38−, CD34+CD38+, and CD10+Hematopoietic Stem and Progenitor Cells in the Peripheral Blood of B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Suggest the Presence of Additional Therapeutic Target Cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.